Skip to main content
Premium Trial:

Request an Annual Quote

DuPont, Caribou Biosciences Ink Strategic Alliance on CRISPR, Cross-License IP

NEW YORK (GenomeWeb) – DuPont and Caribou Biosciences today announced a strategic alliance focused on agricultural applications of CRISPR/Cas9 genome editing.

Under the terms of the agreement, DuPont and Caribou have cross-licensed their patent portfolios. DuPont will receive exclusive intellectual property rights for CRISPR/Cas9 technology for application in row crops and non-exclusive rights in other agricultural and industrial applications.

The agreement also stipulates a multi-year research collaboration between the firms to enhance the CRISPR/Cas9 toolkit. Other financial details of the licensing agreement were not disclosed, though DuPont also has made a minority investment in Caribou for an undisclosed amount.

"DuPont intends to lead in the application of [CRISPR] technology to improve agricultural productivity and enhance food security," DuPont Executive VP James Borel said in a statement, adding that CRISPR/Cas9 has "significant potential to advance plant breeding and expand the range of agricultural solutions available to farmers."

"DuPont has been responsible for numerous breakthroughs in CRISPR biology and we are excited to gain access to their impressive knowledge and expertise in developing and applying Cas-mediated genome editing technologies in promising commercial areas," Caribou President and CEO Rachel Haurwitz said in a statement.

The agreement with Caribou gives DuPont broad license to use CRISPR/Cas9 in ag-bio applications. In June, DuPont acquired an exclusive license to commercial and agricultural uses of CRISPR/Cas9 genome editing technology from Lithuania's Vilnius University.

Caribou has now signed licensing agreements with and received investment from giants in two different industries. In January, Caribou signed a research collaboration and investment agreement with pharmaceutical firm Novartis.

In April it raised $11 million in Series A financing.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.